학술논문
216TiP - OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
Document Type
Abstract
Author
Source
In Annals of Oncology September 2017 28 Supplement 5:v67-v67
Subject
Language
ISSN
0923-7534